Gain Therapeutics

Ticker: NASDAQ: GANX Founded: 2017 Headquarters: Bethesda, Maryland, USA CEO: Robert L. J. W. Hopf Status: Public company Market Cap: ~$30 million (2026) Website: [gaintherapeutics.com](https://www.gaintherapeutics.com)

Overview

Gain Therapeutics is a clinical-stage biotechnology company developing small molecule therapeutic chaperones for neurodegenerative diseases and lysosomal storage disorders. Founded in 2017 and headquartered in Bethesda, Maryland, Gain utilizes a proprietary computational platform called SEE-Tx (Site-Directed Excipient Engineering for Therapeutic molecules) to identify small molecules that can stabilize and restore function to misfolded proteins[@gain2026].

The company's approach represents a paradigm shift in treating protein misfolding diseases — rather than attempting to clear accumulated toxic proteins or replace missing enzymes entirely, Gain's therapeutic chaperones help restore the natural function of endogenous proteins. This approach has the potential to modify disease progression rather than merely addressing symptoms.

Gain Therapeutics went public in 2021, listing on the NASDAQ stock exchange under the ticker GANX. The company has raised over $40 million through its IPO and subsequent financing rounds to advance its clinical pipeline.

Company History

Founding and Early Development

Ticker: NASDAQ: GANX Founded: 2017 Headquarters: Bethesda, Maryland, USA CEO: Robert L. J. W. Hopf Status: Public company Market Cap: ~$30 million (2026) Website: [gaintherapeutics.com](https://www.gaintherapeutics.com)

Overview

Gain Therapeutics is a clinical-stage biotechnology company developing small molecule therapeutic chaperones for neurodegenerative diseases and lysosomal storage disorders. Founded in 2017 and headquartered in Bethesda, Maryland, Gain utilizes a proprietary computational platform called SEE-Tx (Site-Directed Excipient Engineering for Therapeutic molecules) to identify small molecules that can stabilize and restore function to misfolded proteins[@gain2026].

The company's approach represents a paradigm shift in treating protein misfolding diseases — rather than attempting to clear accumulated toxic proteins or replace missing enzymes entirely, Gain's therapeutic chaperones help restore the natural function of endogenous proteins. This approach has the potential to modify disease progression rather than merely addressing symptoms.

Gain Therapeutics went public in 2021, listing on the NASDAQ stock exchange under the ticker GANX. The company has raised over $40 million through its IPO and subsequent financing rounds to advance its clinical pipeline.

Company History

Founding and Early Development

Gain Therapeutics was founded based on research conducted at the University of Maryland and Johns Hopkins University, with a focus on applying computational biology to protein stabilization. The company's SEE-Tx platform emerged from over a decade of academic research on protein misfolding and therapeutic chaperone design.

The company's name reflects its core scientific approach — "Gain" refers to gaining function, as opposed to the loss of function that characterizes many neurodegenerative diseases. This naming reflects the company's mission to develop therapies that restore protein function rather than simply reducing toxic protein accumulation.

Corporate Milestones

| Year | Event |
|------|-------|
| 2017 | Company founded in Bethesda, MD |
| 2018 | Series A financing: $5.5 million |
| 2020 | Series B financing: $12 million; SEE-Tx platform validated |
| 2021 | IPO on NASDAQ: $25 million gross proceeds |
| 2023 | GT-02287 enters Phase 1 clinical trials |
| 2024 | Phase 1b trial initiated in [GBA1](/entities/gba)-PD |
| 2025 | Phase 1b interim data expected |

Platform Technology

SEE-Tx Computational Platform

The proprietary SEE-Tx (Site-Directed Excipient Engineering for Therapeutic molecules) platform represents Gain's core technological advantage. This computational approach enables the identification of small molecule chaperones that can stabilize misfolded proteins[@gain2026a].

Key capabilities include:

• Structure-based design: Leveraging protein crystal structures and computational modeling to identify binding sites
• Allosteric modulation: Targeting sites distant from the active site to stabilize the native protein conformation
• Blood-brain barrier optimization: Designing molecules with properties suitable for CNS penetration
• Rapid screening: Computational prediction allows testing of thousands of virtual compounds before experimental validation

Platform Differentiation

Unlike traditional drug discovery approaches that focus on inhibiting or activating protein function, SEE-Tx is specifically designed to restore protein function. This makes it particularly applicable to:

• Protein misfolding diseases: Where the native protein sequence is present but adopts an abnormal conformation
• Lysosomal storage disorders: Where enzyme function is reduced due to misfolding rather than gene deletion
• Neurodegenerative diseases: Where protein aggregation drives disease pathology

Technology Validation

The SEE-Tx platform has been validated across multiple protein targets:

• Glucocerebrosidase (GCase): Lead program GT-02287
• Galactosylceramidase (GALC): Krabbe disease program
• Beta-galactosidase (GLB1): GM1 gangliosidosis program
• Alpha-galactosidase A (GLA): Fabry disease program

Clinical Pipeline

GT-02287 (Lead Clinical Program)

GT-02287 is Gain's lead clinical candidate — a small molecule glucocerebrosidase (GCase) modulator for the treatment of Parkinson's disease[@gain2026b].

Mechanism of Action:
GT-02287 is an allosteric small molecule chaperone that binds to GCase, stabilizing its proper conformation and increasing enzyme activity. This approach addresses the underlying enzymatic deficiency that contributes to Parkinson's disease pathology.

Pharmacological Properties:

• Blood-brain barrier penetrant
• Once-daily oral administration
• Restoration of GCase activity toward wild-type levels
• Reduced accumulation of glucosylceramide and related glycosphingolipids

• Phase 1a: Single ascending dose study completed in healthy volunteers — favorable safety and PK profile
• Phase 1b: Multiple ascending dose study in patients with GBA1-associated Parkinson's disease and idiopathic PD (NCT06732180)
• Expected interim data: Mid-2025

• Lead: GBA1-associated Parkinson's disease (GBA1-PD)
• Secondary: Idiopathic Parkinson's disease
• Exploratory: Dementia with Lewy Bodies, Alzheimer's disease

GT-0234 (Lysosomal Storage Disorder Program)

GT-0234 demonstrates the versatility of the SEE-Tx platform across therapeutic areas. This candidate targets Pompe disease, a lysosomal storage disorder caused by deficiency of acid alpha-glucosidase (GAA).

Current Status: Preclinical development

Preclinical Pipeline

| Program | Indication | Target | Development Stage |
|---------|------------|--------|-------------------|
| GT-02287 | Neuronopathic Gaucher Disease | GCase | Preclinical |
| GT-02287 | Dementia with Lewy Bodies | GCase | Preclinical |
| GT-02287 | [Alzheimer's Disease](/diseases/alzheimers-disease) | GCase | Preclinical |
| GT-02287 | Parkinson's Disease (idiopathic) | GCase | Phase 1b |
| GT-0234 | Pompe Disease | GAA | Preclinical |
| Undisclosed | GM1 Gangliosidosis | GLB1 | Preclinical |
| Undisclosed | Krabbe Disease | GALC | Discovery |
| Undisclosed | Fabry Disease | GLA | Research |

Research Programs

Gain maintains an active research portfolio exploring additional targets:

• Alpha-1 antitrypsin deficiency (AAT): Exploring chaperone approaches for this proteopathy
• Oncology applications: DDR2 inhibitors for solid tumors
• Additional lysosomal storage disorders: Platform expansion opportunities

Science and Rationale

Glucocerebrosidase and Neurodegeneration

Glucocerebrosidase (GCase) is a lysosomal enzyme encoded by the GBA1 gene that catalyzes the hydrolysis of glucosylceramide to ceramide and glucose[@gba2026]. This enzyme plays a critical role in lipid metabolism within lysosomes.

GCase dysfunction contributes to neurodegeneration through multiple mechanisms:

GBA1 and Parkinson's Disease

Mutations in the GBA1 gene represent the most common genetic risk factor for Parkinson's disease:

• Heterozygous GBA1 mutations increase Parkinson's disease risk 5-20x depending on specific mutation
• GBA1-associated PD (GBA1-PD) accounts for approximately 5-10% of all Parkinson's disease cases
• Phenotype: GBA1-PD typically has earlier onset and more rapid progression than idiopathic PD
• Neuropathology: Often presents with both Lewy body pathology and evidence of Gaucher disease-related changes

Therapeutic Chaperone Approach

Gain's therapeutic chaperone approach offers several advantages over alternative strategies:

Compared to enzyme replacement therapy:

• Can cross the blood-brain barrier
• Works intracellularly to restore endogenous protein
• Potential for disease modification
• Lower immunogenicity risk

• Oral bioavailability
• Reversible dosing
• Lower development and manufacturing costs
• Established regulatory pathway

• Targets intracellular protein
• Lower cost of goods
• Once-daily oral dosing potential

Business Strategy

Focus Areas

Gain's strategic priorities center on three main areas:

Partnership Opportunities

Gain seeks strategic partnerships to accelerate development:

• Pharmaceutical partnerships: Co-development and commercialization agreements
• Academic collaborations: Access to novel targets and validation studies
• Patient advocacy partnerships: Clinical trial enrollment and regulatory interactions

Competitive Landscape

Gain competes with other companies developing Parkinson's disease therapies:

• Biogen: GCase-targeting antibodies (failed in clinical trials)
• Sanofi/Provention Bio: GCase modulators
• Various gene therapy companies: GBA1 gene therapy approaches
• Other small molecule approaches: Neuroprotective and symptomatic treatments

Financial Overview

Stock Information

• Exchange: NASDAQ
• Ticker: GANX
• Market Cap: ~$30 million (March 2026)
• 52-week range: $1.50 - $8.00

Funding History

| Event | Year | Amount | Notes |
|-------|------|--------|-------|
| Seed | 2017 | $2 million | Founder funding |
| Series A | 2018 | $5.5 million | Product development |
| Series B | 2020 | $12 million | Platform expansion |
| IPO | 2021 | $25 million | Public offering |
| PIPE | 2022 | $8 million | Post-IPO financing |

Research and Development Expenses

Gain's R&D expenses have increased as programs advance into clinical development:

• 2023: ~$12 million
• 2024: ~$18 million
• 2025 (projected): ~$25 million

Governance and Leadership

Executive Team

• Robert L. J. W. Hopf, PhD, MBA — Chief Executive Officer
• Eric I. Richman, PhD — Chief Scientific Officer
• Joanne M. T. Polistico, CPA — Chief Financial Officer
• Michele A. Gallo, JD — Chief Business Officer

Board of Directors

The board includes representatives from pharmaceutical development, finance, and biotech industry leadership.

Scientific Advisory Board

Leading academic and industry scientists provide guidance on drug development strategy and scientific direction.

Corporate Social Responsibility

Patient Access Programs

Gain is committed to ensuring patients can access its therapies:

• Expanded access programs for eligible patients
• Patient assistance programs for clinical trial participants
• Collaboration with patient advocacy organizations

Environmental, Social, and Governance

Gain maintains commitment to responsible corporate practices:

• Diversity and inclusion in hiring
• Sustainable laboratory practices
• Transparent corporate governance

Future Outlook

Looking ahead, Gain Therapeutics is positioned to achieve several key milestones:

Near-term (2025-2026)

• Phase 1b interim data for GT-02287
• Potential initiation of Phase 2 trials in GBA1-PD
• Expansion of preclinical pipeline

Medium-term (2026-2028)

• Phase 2/3 trial initiation for lead indication
• Business development partnerships
• Pipeline expansion in Alzheimer's disease

Long-term (2028+)

• Potential NDA submission
• Commercial launch preparation
• Platform expansion to additional targets

Related Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [GBA1 Gene](/genes/gba1)
• [Glucocerebrosidase](/proteins/glucocerebrosidase)
• [Alpha-synuclein](/proteins/alpha-synuclein)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
• [Protein Misfolding Pathway](/mechanisms/protein-misfolding)
• [Therapeutic Chaperones](/technologies/therapeutic-chaperones)
• [Blood-Brain Barrier](/entities/blood-brain-barrier)
• [Neurodegeneration Mechanisms](/diseases/neurodegeneration)

External Links

• [Gain Therapeutics Official Website](https://www.gaintherapeutics.com)
• [NASDAQ: GANX](https://www.nasdaq.com/market-activity/stocks/ganx)
• [ClinicalTrials.gov - GT-02287](https://clinicaltrials.gov/study/NCT06732180)
• [SEC Filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001824801)

References